Jazz Pharmaceuticals price target lowered to $254 from $256 at Truist
Truist analyst Gregory Renza lowered the firm's price target on Jazz Pharmaceuticals to $254 from $256 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the yea